Vivozon Pharmaceutical

비보존 제약 · 082800

Health Care Pharmaceuticals · KOSDAQ

Small-cap

Market cap US$124.5M (₩171.8B)

Overview

Vivozon Pharmaceutical makes finished medicines, including treatments for circulatory conditions, diabetes, fever and pain relief, skin conditions, and influenza, supplied to patients through prescription and over-the-counter channels in Korea.

It is listed on KOSDAQ, Korea's tech and small-cap exchange. Beyond its own branded products, the company also operates contract manufacturing and private-label production businesses, giving it multiple revenue streams across its portfolio of well over a hundred product lines.

Summary is AI-generated and may contain errors · figures from DART filings

Financials

Source: DART · FY ending Dec · latest FY2025

Revenue · FY2025

US$43M

▼ −32.3% YoY

Operating profit · FY2025

−US$13.9M

Turned to loss

Net income · FY2025

−US$23.5M

Loss widened

Revenue, operating profit and net income by fiscal year (USD; KRW in parentheses).
Metric	FY2023	FY2024	FY2025
Revenue	US$51.7M(₩71.3B)	US$63.5M(₩87.6B)	US$43M(₩59.3B)
Operating profit	US$1.9M(₩2.6B)	US$2.1M(₩2.9B)	−US$13.9M(−₩19.2B)
Net income	−US$2.4M(−₩3.4B)	−US$7.2M(−₩10B)	−US$23.5M(−₩32.4B)

Revenue

FY2023US$51.7M
FY2024US$63.5M
FY2025US$43M

Operating profit

FY2023US$1.9M
FY2024US$2.1M
FY2025−US$13.9M

Net income

FY2023−US$2.4M
FY2024−US$7.2M
FY2025−US$23.5M

Key ratios (FY2025)

ROE

-44.6%

Debt/Eq

127.7%

Op. margin

-32.3%

Net margin

-54.6%

Rev. YoY

▼ −32.3%

Price charts coming soon

Interactive price history isn't here yet. Would you use it?